SpliSense

SpliSenseSpliSense
SpliSense

SpliSense

Biotechnology company developing inhaled therapies for genetic diseases, focusing on Cystic Fibrosis.

Website
2017Active16Rehovot, Israel
Rate
Advertise here

About

SpliSense is a biotechnology company developing transformative RNA-based treatments for pulmonary diseases. Their innovative therapies utilize Antisense Oligonucleotides (ASOs) to restore and modify protein functionality, targeting the root cause of conditions like Cystic Fibrosis and Muco-Obstructive Pulmonary Diseases.
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does SpliSense do?

SpliSense is a biotechnology company developing transformative RNA-based treatments for pulmonary diseases. Their innovative therapies utilize Antisense Oligonucleotides (ASOs) to restore and modify protein functionality, targeting the root cause of conditions like Cystic Fibrosis and Muco-Obstructive Pulmonary Diseases.

How much funding has SpliSense raised?

SpliSense has raised a total of $29M in funding. The most recent round on record is Series B.

Where is SpliSense headquartered?

SpliSense is headquartered in Rehovot, Israel.

When was SpliSense founded?

SpliSense was founded in 2017.

What industry does SpliSense operate in?

SpliSense operates in Healthcare, Lung, Treatment, Biotech, Cystic Fibrosis, mRNA.

How many employees does SpliSense have?

SpliSense has approximately 16 people on record.

What is SpliSense's revenue?

StartupHub estimates SpliSense's annual revenue at $4.5M (range $2.5M to $8.2M, 63% confidence), based on comparable companies in the sector.

What is SpliSense's valuation?

StartupHub estimates SpliSense's effective valuation at $114.0M (range $71.3M to $171.0M, 10% confidence), based on comparable companies in the sector.